A Specific STAT3-Binding Peptide Exerts Antiproliferative Effects and Antitumor Activity by Inhibiting STAT3 Phosphorylation and Signaling

These results offer preclinical proof of concept for a novel type of bioactive STAT3 inhibitor that may be tractable for clinical development, addressing a long-standing challenge to target the broad array of cancers harboring constitutively activated STAT3.